Omeros Current Deferred Revenue History
| OMER Stock | USD 13.53 0.01 0.07% |
Current Deferred Revenue | First Reported 2008-12-31 | Previous Quarter 34.9 M | Current Value -42.1 M | Quarterly Volatility 11 M |
Macro event markers
Latest Omeros Current Deferred Revenue Growth Pattern
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Current Deferred Revenue Trend Statistics
Over 8 reporting periods, Omeros' Current Deferred Revenue shows a coefficient of variation of 1476.4%, indicating elevated dispersion relative to the mean. An R-squared of 0.35 points to a moderate linear trend with partial explanatory power.| Arithmetic Mean | -108,659 | |
| Geometric Mean | 643,772 | |
| Coefficient Of Variation | -1,476 | |
| Mean Deviation | 887,527 | |
| Median | -760,095 | |
| Standard Deviation | 1,604,228 | |
| Sample Variance | 2.6T | |
| Range | 6.6M | |
| R-Value | -0.60 | |
| Mean Square Error | 1.8T | |
| R-Squared | 0.35 | |
| Significance | 0.01 | |
| Slope | -189,080 | |
| Total Sum of Squares | 41.2T |
Omeros Current Deferred Revenue History
Omeros reports Current Deferred Revenue from 2010 through 2026 across 8 observations, beginning at 500 K and ending at -760.1 K.Correlation of Current Deferred Revenue With Other Accounts
Correlation values indicate the degree of linear co-movement between Omeros' Current Deferred Revenue and other reported accounts. Values near +1 or −1 suggest strong association; values near 0 suggest independence. These relationships are descriptive and do not imply causation.Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Deferred Long Term Liabilities | 9.4 M | 4.8 M | |
| Depreciation And Amortization | 964 K | 748.4 K | |
| Other Operating Expenses | 122.8 M | 99.2 M | |
| Operating Income | -122.8 M | -128.9 M | |
| EBIT | -122.8 M | -116.7 M | |
| Research Development | 81.3 M | 65.4 M |
Methodology, Assumptions & Data Sources
The Current Deferred Revenue trend for Omeros is contextualized below with regression and dispersion statistics. Benchmarking this metric against sector peers distinguishes company-specific movement from industry-wide patterns. Within the Pharmaceuticals sector, Omeros' Current Deferred Revenue reflects the revenue and cost dynamics of its operating model.
Omeros values are built from periodic company reporting and market reference feeds, with reporting definitions aligned before display. Where analyst coverage exists, consensus estimates are factored in. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board